VIDA Resonance

Imaging Biomarkers: Analysis of medical imaging transforming your data into validated quantitative biomarkers and insights that empower discovery and trial decision-making.

Connect with an Expert
VIDA Resonance visualization

Unlocking Long-Term Value from Clinical Imaging Data

VIDA Resonance transforms medical imaging and trial operations into a continuous source of quantitative intelligence. By applying AI-augmented workflows, VIDA Resonance generates actionable insights across the entire research lifecycle. Replacing subjective, point-in-time visual interpretation with continuous, quantitative intelligence enables real-time decisions, strengthens study execution, and builds endpoint confidence — while creating a reusable, long-term imaging data asset.

How VIDA Resonance Works

Amplify Clinical & Operational Understanding

Continuously tap into the value of imaging assets that has been collected either through a formalized trial or RWD sources. Generate new biomarkers, visualize new patterns, explore correlations, all to increase understanding patient response.

Key AdvantagesUnleash Imaging

VIDA Resonance Expands Insights for Research

Continuously leverage imaging assets for new insights, modeling response, plan future trials and commercialization.

Create, Combine, & Expand Data

Take existing trial, research, and RWD to form/mine new imaging cohorts.

Explore Disease Response Models

Add new biomarkers, find patterns, and build/validate understanding of response.

Right Subjects, Right Sites

Use established biomarker patterns and site performance to plan future trials and actions.

VIDA Resonance in Action

Illustrative Example

  • A new imaging biomarker (airway mucus density) become available after a trial is complete. The sponsor performs a sub-analysis of the strongest responders to see if mucus density was a common factor.

Illustrative Example

  • A sponsor is planning a new study and selecting sites. They dive into the operational data within the Digital Biobank to find the best performing sites over the past two trials.